Literature DB >> 3484703

Completion of the primary structure of human high-molecular-mass kininogen. The amino acid sequence of the entire heavy chain and evidence for its evolution by gene triplication.

J Kellermann, F Lottspeich, A Henschen, W Müller-Esterl.   

Abstract

The amino acid sequence of the heavy chain of human high-molecular-mass kininogen has been determined. It completes the primary structure of the high-Mr kininogen molecule. The heavy chain contains 362, the total kininogen molecule 626 amino acid residues. Three carbohydrate side chains were found in the heavy chain, all of them N-glycosidically linked to asparagine, which is present in the acceptor sequon Asn-Xaa-Thr (or -Ser); one additional potential glycosylation site devoid of a sugar side chain is found at position 30. There is a high degree of homology between the heavy chains of human high-Mr kininogen and bovine high-Mr kininogen (74% identity), or rat T-kininogen (61%). Comparison of the primary structure of human high-Mr kininogen with that of human low-Mr kininogen predicted from its cDNA sequence, reveals that the heavy chains of the two human kininogens are completely identical. Two heavy chain segments believed to contain the reactive sites for cysteine proteinase inhibition show an extensive sequence homology with other mammalian cysteine proteinase inhibitors. Within the heavy chain of human high-Mr kininogen are repetitive units strongly suggesting that the heavy chain of human kininogens has evolved from at least two ancestral units by a series of gene duplication and fusion events.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484703     DOI: 10.1111/j.1432-1033.1986.tb09421.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  14 in total

1.  Evolution of proteins of the cystatin superfamily.

Authors:  N D Rawlings; A J Barrett
Journal:  J Mol Evol       Date:  1990-01       Impact factor: 2.395

2.  Amino acid distributions around O-linked glycosylation sites.

Authors:  I B Wilson; Y Gavel; G von Heijne
Journal:  Biochem J       Date:  1991-04-15       Impact factor: 3.857

Review 3.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 4.  Friends and relations of the cystatin superfamily--new members and their evolution.

Authors:  W M Brown; K M Dziegielewska
Journal:  Protein Sci       Date:  1997-01       Impact factor: 6.725

Review 5.  Calmodulin-binding proteins as calpain substrates.

Authors:  K K Wang; A Villalobo; B D Roufogalis
Journal:  Biochem J       Date:  1989-09-15       Impact factor: 3.857

6.  Arrangement of the disulphide bridges in human low-Mr kininogen.

Authors:  J Kellermann; C Thelen; F Lottspeich; A Henschen; R Vogel; W Müller-Esterl
Journal:  Biochem J       Date:  1987-10-01       Impact factor: 3.857

7.  High-affinity binding of two molecules of cysteine proteinases to low-molecular-weight kininogen.

Authors:  B Turk; V Stoka; I Björk; C Boudier; G Johansson; I Dolenc; A Colic; J G Bieth; V Turk
Journal:  Protein Sci       Date:  1995-09       Impact factor: 6.725

8.  Solution phase conformation studies of the prekallikrein binding domain of high molecular weight kininogen.

Authors:  J N Scarsdale; R B Harris
Journal:  J Protein Chem       Date:  1990-10

9.  Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release.

Authors:  Narayanan Parthasarathy; Suzy V Torti; Frank M Torti
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

10.  Pathogenesis of periodontitis: a major arginine-specific cysteine proteinase from Porphyromonas gingivalis induces vascular permeability enhancement through activation of the kallikrein/kinin pathway.

Authors:  T Imamura; R N Pike; J Potempa; J Travis
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.